Comprehensive Analysis of m5C RNA Methylation Regulator Genes in Clear Cell Renal Cell Carcinoma

Jiajin Wu1, Chao Hou1, Yuhao Wang1

  • 1The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing 210029, China.

Abstract

Insights

This study developed a new risk signature using seven m5C RNA methylation regulators to predict clear cell renal cell carcinoma (ccRCC) patient outcomes. This signature shows excellent prognostic prediction and identifies potential immune cell differences in ccRCC.

Area of Science:

  • Oncology
  • Epigenetics
  • Bioinformatics

Background:

  • N5-methylcytosine (m5C) RNA methylation is implicated in various cancers.
  • The role of m5C regulators in clear cell renal cell carcinoma (ccRCC) remains unclear.
  • This study investigates the clinical and predictive value of m5C regulators in ccRCC.

Purpose of the Study:

  • To explore the function and mechanism of m5C RNA methylation regulators in ccRCC.
  • To identify predictive biomarkers for ccRCC prognosis.
  • To develop a risk signature for ccRCC based on m5C-related genes.

Main Methods:

  • Utilized The Cancer Genome Atlas (TCGA) database for gene expression and clinical data analysis.
  • Employed consensus clustering, univariate Cox, and LASSO Cox regression to construct and validate a risk signature.
  • Performed functional annotation, ssGSEA, and qRT-PCR for biological pathway and methylation level validation.

Main Results:

  • Identified significant differences in m5C regulator expression between ccRCC and normal tissues.
  • Developed a seven-gene m5C RNA methylation-related risk signature with excellent prognostic prediction (AUCs 0.792, 0.675, 0.709 for 1, 2, 3 years).
  • Found the risk signature to be an independent prognostic factor and revealed distinct immune cell infiltration and function differences between high- and low-risk groups.

Conclusions:

  • A novel risk signature based on seven m5C RNA methylation regulators was developed for ccRCC.
  • This signature effectively and independently predicts prognosis in ccRCC patients.
  • The findings highlight the role of m5C methylation in ccRCC and its potential impact on the tumor immune microenvironment.